Mantle Cell Lymphoma - Pipeline Review, H2 2016

Date: August 10, 2016
Pages: 426
Price:
US$ 2,000.00
License [?]:
Publisher: Global Markets Direct
Report type: Strategic Report
Delivery: E-mail Delivery (PDF)
ID: MF41D6C8C22EN
Leaflet:

Download PDF Leaflet

Mantle Cell Lymphoma - Pipeline Review, H2 2016

SUMMARY

Global Markets Direct’s, ‘Mantle Cell Lymphoma - Pipeline Review, H2 2016’, provides an overview of the Mantle Cell Lymphoma pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Mantle Cell Lymphoma, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Mantle Cell Lymphoma and features dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note: Certain sections in the report may be removed or altered based on the availability and relevance of data.

SCOPE
  • The report provides a snapshot of the global therapeutic landscape of Mantle Cell Lymphoma
  • The report reviews pipeline therapeutics for Mantle Cell Lymphoma by companies and universities/research institutes based on information derived from company and industry-specific sources
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved Mantle Cell Lymphoma therapeutics and enlists all their major and minor projects
  • The report assesses Mantle Cell Lymphoma therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report summarizes all the dormant and discontinued pipeline projects
  • The report reviews latest news related to pipeline therapeutics for Mantle Cell Lymphoma
REASONS TO BUY
  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand important and diverse types of therapeutics under development for Mantle Cell Lymphoma
  • Identify potential new clients or partners in the target demographic
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding Mantle Cell Lymphoma pipeline depth and focus of Indication therapeutics
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Introduction
Global Markets Direct Report Coverage
Mantle Cell Lymphoma Overview
Therapeutics Development
Pipeline Products for Mantle Cell Lymphoma - Overview
Pipeline Products for Mantle Cell Lymphoma - Comparative Analysis
Mantle Cell Lymphoma - Therapeutics under Development by Companies
Mantle Cell Lymphoma - Therapeutics under Investigation by Universities/Institutes
Mantle Cell Lymphoma - Pipeline Products Glance
Late Stage Products
Clinical Stage Products
Early Stage Products
Mantle Cell Lymphoma - Products under Development by Companies
Mantle Cell Lymphoma - Products under Investigation by Universities/Institutes
Mantle Cell Lymphoma - Companies Involved in Therapeutics Development
AB Science SA
AbbVie Inc
Acetylon Pharmaceuticals, Inc.
Actinium Pharmaceuticals, Inc.
Affimed GmbH
Amgen Inc.
Asana BioSciences, LLC
Astellas Pharma Inc.
Astex Pharmaceuticals, Inc.
Bayer AG
BeiGene, Ltd.
Bristol-Myers Squibb Company
Celgene Corporation
Cellular Biomedicine Group, Inc.
Eisai Co., Ltd.
Eli Lilly and Company
EpiZyme, Inc.
Gilead Sciences, Inc.
GlaxoSmithKline Plc
Hutchison MediPharma Limited
ImmunoGen, Inc.
Immunomedics, Inc.
Incyte Corporation
Inflection Biosciences Limited
Johnson & Johnson
Juno Therapeutics Inc.
Karyopharm Therapeutics, Inc.
Kite Pharma, Inc.
LFB S.A.
MacroGenics, Inc.
MedImmune, LLC
Merck & Co., Inc.
Merck KGaA
Millennium Pharmaceuticals Inc
MorphoSys AG
Nordic Nanovector ASA
Novartis AG
Onconova Therapeutics, Inc.
Oncternal Therapeutics, Inc.
Patrys Limited
Pharmacyclics, Inc.
Portola Pharmaceuticals, Inc.
Seattle Genetics, Inc.
Selvita S.A.
Stemline Therapeutics, Inc.
Takeda Pharmaceutical Company Limited
TG Therapeutics, Inc.
Vivolux AB
Mantle Cell Lymphoma - Therapeutics Assessment
Assessment by Monotherapy Products
Assessment by Combination Products
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Drug Profiles
(INCB-039110 + INCB-040093) - Drug Profile
13197 - DRUG PROFILE
AB-8779 - Drug Profile
abexinostat hydrochloride - Drug Profile
acalabrutinib - Drug Profile
ACY-241 - Drug Profile
ACY-775 - Drug Profile
AFM-11 - Drug Profile
alisertib - Drug Profile
AMG-319 - Drug Profile
ASN-002 - Drug Profile
AT-7519 - Drug Profile
avicin d - Drug Profile
BC-8Y90 - Drug Profile
bendamustine hydrochloride - Drug Profile
Betalutin - Drug Profile
BGB-3111 - Drug Profile
BLyS-gel - Drug Profile
BMS-986016 - Drug Profile
buparlisib hydrochloride - Drug Profile
carfilzomib - Drug Profile
CBM-C19.1 - Drug Profile
CBM-C20.1 - Drug Profile
Cellular Immunotherapy for Oncology - Drug Profile
Cellular Immunotherapy to Target CD19 for Oncology - Drug Profile
cerdulatinib - Drug Profile
copanlisib hydrochloride - Drug Profile
daratumumab - Drug Profile
denintuzumab mafodotin - Drug Profile
durvalumab - Drug Profile
E-7449 - Drug Profile
entospletinib - Drug Profile
epratuzumab - Drug Profile
EPZ-015666 - Drug Profile
HMPL-523 - Drug Profile
IBL-301 - Drug Profile
ibrutinib - Drug Profile
IGN-002 - Drug Profile
IMGN-529 - Drug Profile
IMMU-114 - Drug Profile
INA-01 - Drug Profile
INCB-40093 - Drug Profile
INCB-50465 - Drug Profile
inebilizumab - Drug Profile
inebilizumab + MEDI-0680 - Drug Profile
Iomab-B - Drug Profile
itacitinib adipate - Drug Profile
ixazomib citrate - Drug Profile
JCAR-014 - Drug Profile
JCAR-015 - Drug Profile
JCAR-017 - Drug Profile
JNJ-64052781 - Drug Profile
KTEC-19 - Drug Profile
LAM-002A - Drug Profile
M-7583 - Drug Profile
Monoclonal Antibodies to Inhibit PD-1/PD-L1 for Hematological Malignancies and Bacterial Infections - Drug Profile
Monoclonal Antibodies to Target ROR1 and CD3 for Oncology - Drug Profile
MOR-208 - Drug Profile
ON-123300 - Drug Profile
ONC-201 - Drug Profile
OSU-2S - Drug Profile
PATLM-1 - Drug Profile
PCAR-019 - Drug Profile
pembrolizumab - Drug Profile
ramucirumab - Drug Profile
ribociclib succinate - Drug Profile
S-055746 - Drug Profile
sapanisertib - Drug Profile
SEL-120 - Drug Profile
SEL-12034 - Drug Profile
SEL-24B489 - Drug Profile
selinexor - Drug Profile
SGN-CD70A - Drug Profile
SL-101 - Drug Profile
spebrutinib besylate - Drug Profile
TAK-659 - Drug Profile
TGR-1202 - Drug Profile
tisagenlecleucel-T - Drug Profile
tretinoin - Drug Profile
ublituximab - Drug Profile
UC-961 - Drug Profile
venetoclax - Drug Profile
VLX-1570 - Drug Profile
vorinostat - Drug Profile
Mantle Cell Lymphoma - Dormant Projects
Mantle Cell Lymphoma - Discontinued Products
Mantle Cell Lymphoma - Product Development Milestones
Featured News & Press Releases
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

LIST OF TABLES

Number of Products under Development for Mantle Cell Lymphoma, H2 2016
Number of Products under Development for Mantle Cell Lymphoma - Comparative Analysis, H2 2016
Number of Products under Development by Companies, H2 2016
Number of Products under Development by Companies, H2 2016 (Contd.1)
Number of Products under Development by Companies, H2 2016 (Contd.2)
Number of Products under Development by Companies, H2 2016 (Contd.3)
Number of Products under Investigation by Universities/Institutes, H2 2016
Comparative Analysis by Late Stage Development, H2 2016
Comparative Analysis by Clinical Stage Development, H2 2016
Comparative Analysis by Early Stage Development, H2 2016
Products under Development by Companies, H2 2016
Products under Development by Companies, H2 2016 (Contd.1)
Products under Development by Companies, H2 2016 (Contd.2)
Products under Development by Companies, H2 2016 (Contd.3)
Products under Development by Companies, H2 2016 (Contd.4)
Products under Investigation by Universities/Institutes, H2 2016
Mantle Cell Lymphoma - Pipeline by AB Science SA, H2 2016
Mantle Cell Lymphoma - Pipeline by AbbVie Inc, H2 2016
Mantle Cell Lymphoma - Pipeline by Acetylon Pharmaceuticals, Inc., H2 2016
Mantle Cell Lymphoma - Pipeline by Actinium Pharmaceuticals, Inc., H2 2016
Mantle Cell Lymphoma - Pipeline by Affimed GmbH, H2 2016
Mantle Cell Lymphoma - Pipeline by Amgen Inc., H2 2016
Mantle Cell Lymphoma - Pipeline by Asana BioSciences, LLC, H2 2016
Mantle Cell Lymphoma - Pipeline by Astellas Pharma Inc., H2 2016
Mantle Cell Lymphoma - Pipeline by Astex Pharmaceuticals, Inc., H2 2016
Mantle Cell Lymphoma - Pipeline by Bayer AG, H2 2016
Mantle Cell Lymphoma - Pipeline by BeiGene, Ltd., H2 2016
Mantle Cell Lymphoma - Pipeline by Bristol-Myers Squibb Company, H2 2016
Mantle Cell Lymphoma - Pipeline by Celgene Corporation, H2 2016
Mantle Cell Lymphoma - Pipeline by Cellular Biomedicine Group, Inc., H2 2016
Mantle Cell Lymphoma - Pipeline by Eisai Co., Ltd., H2 2016
Mantle Cell Lymphoma - Pipeline by Eli Lilly and Company, H2 2016
Mantle Cell Lymphoma - Pipeline by EpiZyme, Inc., H2 2016
Mantle Cell Lymphoma - Pipeline by Gilead Sciences, Inc., H2 2016
Mantle Cell Lymphoma - Pipeline by GlaxoSmithKline Plc, H2 2016
Mantle Cell Lymphoma - Pipeline by Hutchison MediPharma Limited, H2 2016
Mantle Cell Lymphoma - Pipeline by ImmunoGen, Inc., H2 2016
Mantle Cell Lymphoma - Pipeline by Immunomedics, Inc., H2 2016
Mantle Cell Lymphoma - Pipeline by Incyte Corporation, H2 2016
Mantle Cell Lymphoma - Pipeline by Inflection Biosciences Limited, H2 2016
Mantle Cell Lymphoma - Pipeline by Johnson & Johnson, H2 2016
Mantle Cell Lymphoma - Pipeline by Juno Therapeutics Inc., H2 2016
Mantle Cell Lymphoma - Pipeline by Karyopharm Therapeutics, Inc., H2 2016
Mantle Cell Lymphoma - Pipeline by Kite Pharma, Inc., H2 2016
Mantle Cell Lymphoma - Pipeline by LFB S.A., H2 2016
Mantle Cell Lymphoma - Pipeline by MacroGenics, Inc., H2 2016
Mantle Cell Lymphoma - Pipeline by MedImmune, LLC, H2 2016
Mantle Cell Lymphoma - Pipeline by Merck & Co., Inc., H2 2016
Mantle Cell Lymphoma - Pipeline by Merck KGaA, H2 2016
Mantle Cell Lymphoma - Pipeline by Millennium Pharmaceuticals Inc, H2 2016
Mantle Cell Lymphoma - Pipeline by MorphoSys AG, H2 2016
Mantle Cell Lymphoma - Pipeline by Nordic Nanovector ASA, H2 2016
Mantle Cell Lymphoma - Pipeline by Novartis AG, H2 2016
Mantle Cell Lymphoma - Pipeline by Onconova Therapeutics, Inc., H2 2016
Mantle Cell Lymphoma - Pipeline by Oncternal Therapeutics, Inc., H2 2016
Mantle Cell Lymphoma - Pipeline by Patrys Limited, H2 2016
Mantle Cell Lymphoma - Pipeline by Pharmacyclics, Inc., H2 2016
Mantle Cell Lymphoma - Pipeline by Portola Pharmaceuticals, Inc., H2 2016
Mantle Cell Lymphoma - Pipeline by Seattle Genetics, Inc., H2 2016
Mantle Cell Lymphoma - Pipeline by Selvita S.A., H2 2016
Mantle Cell Lymphoma - Pipeline by Stemline Therapeutics, Inc., H2 2016
Mantle Cell Lymphoma - Pipeline by Takeda Pharmaceutical Company Limited, H2 2016
Mantle Cell Lymphoma - Pipeline by TG Therapeutics, Inc., H2 2016
Mantle Cell Lymphoma - Pipeline by Vivolux AB, H2 2016
Assessment by Monotherapy Products, H2 2016
Assessment by Combination Products, H2 2016
Number of Products by Stage and Target, H2 2016
Number of Products by Stage and Mechanism of Action, H2 2016
Number of Products by Stage and Route of Administration, H2 2016
Number of Products by Stage and Molecule Type, H2 2016
Mantle Cell Lymphoma - Dormant Projects, H2 2016
Mantle Cell Lymphoma - Dormant Projects (Contd.1), H2 2016
Mantle Cell Lymphoma - Dormant Projects (Contd.2), H2 2016
Mantle Cell Lymphoma - Discontinued Products, H2 2016

LIST OF FIGURES

Number of Products under Development for Mantle Cell Lymphoma, H2 2016
Number of Products under Development for Mantle Cell Lymphoma - Comparative Analysis, H2 2016
Number of Products under Development by Companies, H2 2016
Number of Products under Investigation by Universities/Institutes, H2 2016
Comparative Analysis by Late Stage Development, H2 2016
Comparative Analysis by Clinical Stage Development, H2 2016
Comparative Analysis by Early Stage Products, H2 2016
Assessment by Monotherapy Products, H2 2016
Number of Products by Top 10 Targets, H2 2016
Number of Products by Stage and Top 10 Targets, H2 2016
Number of Products by Top 10 Mechanism of Actions, H2 2016
Number of Products by Stage and Top 10 Mechanism of Actions, H2 2016
Number of Products by Routes of Administration, H2 2016
Number of Products by Stage and Routes of Administration, H2 2016
Number of Products by Molecule Types, H2 2016
Number of Products by Stage and Molecule Types, H2 2016

COMPANIES MENTIONED

AB Science SA
AbbVie Inc
Acetylon Pharmaceuticals, Inc.
Actinium Pharmaceuticals, Inc.
Affimed GmbH
Amgen Inc.
Asana BioSciences, LLC
Astellas Pharma Inc.
Astex Pharmaceuticals, Inc.
Bayer AG
BeiGene, Ltd.
Bristol-Myers Squibb Company
Celgene Corporation
Cellular Biomedicine Group, Inc.
Eisai Co., Ltd.
Eli Lilly and Company
EpiZyme, Inc.
Gilead Sciences, Inc.
GlaxoSmithKline Plc
Hutchison MediPharma Limited
ImmunoGen, Inc.
Immunomedics, Inc.
Incyte Corporation
Inflection Biosciences Limited
Johnson & Johnson
Juno Therapeutics Inc.
Karyopharm Therapeutics, Inc.
Kite Pharma, Inc.
LFB S.A.
MacroGenics, Inc.
MedImmune, LLC
Merck & Co., Inc.
Merck KGaA
Millennium Pharmaceuticals Inc
MorphoSys AG
Nordic Nanovector ASA
Novartis AG
Onconova Therapeutics, Inc.
Oncternal Therapeutics, Inc.
Patrys Limited
Pharmacyclics, Inc.
Portola Pharmaceuticals, Inc.
Seattle Genetics, Inc.
Selvita S.A.
Stemline Therapeutics, Inc.
Takeda Pharmaceutical Company Limited
TG Therapeutics, Inc.
Vivolux AB
Skip to top


Diffuse Large B-Cell Lymphoma - Pipeline Review, H2 2016 US$ 2,000.00 Oct, 2016 · 710 pages

Ask Your Question

Mantle Cell Lymphoma - Pipeline Review, H2 2016
Company name*:
Contact person*:
Phone/fax*:
Email*:
Request invoice
Your enquiry:
Please click on a Check Box below to confirm you are not a robot: